HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
Completed
GlaxoSmithKline
Phase 2
2006-06-01
The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the
treatment of patients failing both fludarabine and alemtuzumab.
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
Completed
GlaxoSmithKline
Phase 2
2007-05-01
A Single-Arm, International, Multi-Center Trial of HuMax-CD20 (Ofatumumab), a Fully Human
Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to
Rituximab as Monotherapy or in Combination With Chemotherapy
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients
Completed
GlaxoSmithKline
Phase 2
2007-06-01
To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP
(cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients
with Follicular Lymphoma (FL)
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
Terminated
GlaxoSmithKline
Phase 3
2008-01-01
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a
duration of 24 weeks, followed by a 120 week Open-label Period. The primary purpose of the
study is to demonstrate the efficacy and safety of ofatumumab in reducing clinical signs and
symptoms in adult RA patients who had an inadequate response to TNF-α antagonist therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.